Our platform patented technology and related IP portfolio, collectively re-create the cellular microenvironment niche in-vitro (for disease modeling and drug screening) and in-vivo (for rejuvenation longevity therapy). We use small molecule drugs to target this “druggable” entity, modulating extrinsic and intrinsic factors that influence signal transduction pathways of cells. Using this approach, we are developing efficacious small molecule regenerative cures for rejuvenation and healthy aging.